非酒精性脂肪性肝病发病机制的研究进展

王虎; 滕田; 王莉; 周梦; 闫红茹; 孙莹

doi:10.3969/j.issn.1001-5256.2017.04.039

非酒精性脂肪性肝病发病机制的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.04.039

1. 徐州医科大学
2. 江苏省新药与临床应用重点实验室

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2277
- HTML全文浏览量: 70
- PDF下载量: 536
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-01
- 出版日期: 2017-04-20

Research advances in the pathogenesis of nonalcoholic fatty liver disease

Xuzhou Medical University

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)近年来发展迅速,成为最普遍的肝脏疾病之一。然而,其发病机制目前尚不能完全阐明,也没有被广泛认可的治疗方案。NAFLD发病过程复杂且有多方面因素参与,其中包括胰岛素抵抗、氧化应激、胆汁酸代谢紊乱和自噬等。归纳总结了NAFLD的发病机制,希望为将来进一步的研究和临床治疗提供参考依据。
- 脂肪肝 /
- 胰岛素抗药性 /
- 氧化性应激 /
- 自噬 /
- 综述
Abstract: Nonalcoholic fatty liver disease ( NAFLD) has been developing rapidly in recent years and has become one of the most common liver diseases. However, its pathogenesis remains unclear, and there are no widely accepted therapeutic regimens. NAFLD has a complex pathogenesis with multiple factors involved, including insulin resistance, oxidative stress, bile acid metabolic disorders, and autophagy. This article reviews the pathogenesis of NAFLD in order to provide a reference for further research and clinical treatment in the future.
- fatty liver /
- insulin resistance /
- oxidative stress /
- autophagy /
- review

HTML全文

参考文献(45)

[1]BELLENTANI SF, MARINO M, BEDOGNI G.Epidemiology of non-alcoholic fatty liver disease[J].Dig Dis, 2010, 28 (1) :155-161.

[2]FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol, 2013, 28 (1) :11-17.

[3]YOUNOSSI ZM, STEPANOVA M, RAFIQ N, et al.Pathologic criteria for nonalcoholic steatohepatitis:interprotocol agreement and ability to predict liver-related mortality[J].Hepatology, 2011, 53 (6) :1874-1882.

[4]ZHANG Q, LI H, XIANG XH, et al.A summary of 2015 academic conference of Tianjin Society of Integrated Traditional Chinese and Western Medicine for Liver Diseases[J].J Clin Hepatol, 2016, 2 (32) :404-405. (in Chinese) 张青, 李海, 向晓辉, 等.天津市中西医结合肝病学会2015年度学术年会会议纪要[J].临床肝胆病杂志, 2016, 32 (2) :404-405.

[5]ALAM S, MUSTAFA G, ALAM M, et al.Insulin resistance in development and progression of nonalcoholic fatty liver disease[J].World J Gastrointest Pathophysiol, 2016, 7 (2) :211-217.

[6]YKI-JRVINEN H.Liver fat in the pathogenesis of insulin resistance and type 2 diabetes[J].Dig Dis, 2010, 28 (1) :203-209.

[7]BREA A, PUZO J.Non-alcoholic fatty liver disease and cardiovascular risk[J].Int J Cardiol, 2013, 167 (4) :1109-1117.

[8]OKAZAKI S, SHIOI R, NOGUCHI-YACHIDE T, et al.Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptorα/δ (PPARα/δ) dual agonists[J].Bioorg Med Chem, 2016, 24 (21) :5455-5461.

[9]NEGRESALVAYRE A, AUGE N, AYALA V, et al.Pathological aspects of lipid peroxidation[J].Free Radic Res, 2010, 44 (10) :1125-1171.

[10]QU LL, YU B, LI Z, et al.Gastrodin ameliorates oxidative stress and proinflammatory response in nonalcoholic fatty liver disease through the AMPK/Nrf2 pathway[J].Phytother Res, 2016, 30 (3) :402-411.

[11]XU BB, WANG BY.Nonalcoholic fatty liver disease and serum uric acid[J].J Clin Hepatol, 2016, 3 (32) :437-441. (in Chinese) 徐贝贝, 王炳元.非酒精性脂肪性肝病与血清尿酸[J].临床肝胆病杂志, 2016, 3 (32) :437-441.

[12]NOVO E, BUSLETTA C, BONZO LV, et al.Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells[J].J Hepatol, 2011, 54 (5) :964-974.

[13]YU J, MARSH S, HU J, et al.The pathogenesis of nonalcoholic fatty liver disease:interplay between diet, gut microbiota, and genetic background[J].Gastroenterol Res Pract, 2016, 2016:2862173.

[14]COPPLE BL, LI T.Pharmacology of bile acid receptors:evolution of bile acids from simple detergents to complex signaling molecules[J].Pharmacol Res, 2016, 104:9-21.

[15]SCHAAP FG, TRAUNER M, JANSEN PL.Bile acid receptors as targets for drug development[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (1) :55-67.

[16]CARR RM, REID AE.FXR agonists as therapeutic agents for non-alcoholic fatty liver disease[J].Curr Atheroscler Rep, 2015, 17 (4) :500.

[17]MAZUY C, HELLEBOID A, STAELS B, et al.Nuclear bile acid signaling through the farnesoid X receptor[J].Cell Mol Life Sci, 2015, 72 (9) :1631-1650.

[18]KUMAR DP, ASGHARPOUR A, MIRSHAHI F, et al.Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis[J].J Biol Chem, 2016, 291 (13) :6626-6640.

[19]OLIVEIRA MC, GILGLIONI EH, BOER BA, et al.Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiencyrelated postmenopausal obesity and hepatic steatosis in mice[J].Biochim Biophys Acta, 2016, 1862 (11) :2054-2062.

[20]SATORU K.Choose delicately and reuse adequately:the newly revealed process of autophagy[J].Biol Pharm Bull, 2015, 38 (8) :1098-1103.

[21]AMIR M, CZAJA MJ.Autophagy in nonalcoholic steatohepatitis[J].Expert Rev Gastroenterol Hepatol, 2011, 5 (2) :159-166.

[22]MURROW L, DEBNATH J.Autophagy as a stress-response and quality-control mechanism:implications for cell injury and human disease[J].Annu Rev Pathol, 2013, 8:105-137.

[23]KWANTEN WJ, MARTINET W, MICHIELSEN PP, et al.Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease:a controversial issue[J].World J Gastroenterol, 2014, 20 (23) :7325-7338.

[24]MUKHOPADHYAY S, PANDA PK, SINHA N, et al.Autophagy and apoptosis:where do they meet?[J]Apoptosis, 2014, 19 (4) :555-566.

[25]YOULE RJ, NARENDRA DP.Mechanisms of mitophagy[J].Nat Rev Mol Cell Biol, 2011, 12 (1) :9-14.

[26]ZHENG TY, LI YY, NIE YQ, et al.Impact of intestinal flora on severity of non-alcoholic fatty liver disease[J].J Guangzhou Med Univ, 2016, 44 (1) :9-13. (in Chinese) 郑啼婴, 李瑜元, 聂玉强, 等.肠道菌群对非酒精性脂肪性肝病病变程度的影响[J].广州医科大学学报, 2016, 44 (1) :9-13.

[27]ZENG QF, YANG GL, WANG CF.Application of probiotics in liver diseases[J].Chin J Immunol, 2016, 32 (11) :1711-1714. (in Chinese) 曾庆丰, 杨桂连, 王春风.益生菌在肝脏疾病方面的应用[J].中国免疫学杂志, 2016, 32 (11) :1711-1714.

[28]LE ROY T, LLOPIS M, LEPAGE P, et al.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J].Gut, 2013, 62 (12) :1787-1794.

[29]MUSSO G, CASSADER M, COHNEY S, et al.Emerging liverkidney interactions in nonalcoholic fatty liver disease[J].Trends Mol Med, 2015, 21 (10) :645-662.

[30]KIRPICH IA, MARSANO LS, MCCLAIN CJ.Gut-liver axis, nutrition, and non-alcoholic fatty liver disease[J].Clin Biochem, 2015, 48 (13-14) :923-930.

[31]XU R, ZHANG Z, WANG FS.Liver fbrosis:mechanisms of immune-mediated liver injury[J].Cell Mol Immunol, 2012, 4 (9) :296-301.

[32]TAKEDA N, O'DEA EL, DOEDENS A, et al.Differential activation and antagonistic function of HIF-{alpha}isoforms in macrophages are essential for NO homeostasis[J].Genes Dev, 2010, 24 (5) :491-501.

[33]IBRAHIM J, NGUYEN AH, REHMAN A, et al.Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver[J].Gastroenterology, 2012, 4 (143) :1061-1072.

[34]XUAN SY, YUAN C, LU LL, et al.Research advances in susceptibility genes and their role in the pathogenesis of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2016, 32 (3) :446-452. (in Chinese) 宣世英, 袁晨, 芦琳琳, 等.非酒精性脂肪性肝病相关易感基因及其在发病机制中的作用[J].临床肝胆病杂志, 2016, 32 (3) :446-452.

[35]PINGITORE P, PIRAZZI C, MANCINA RM, et al.Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function[J].Biochim Biophys Acta, 2014, 1841 (4) :574-580.

[36]HE S, MCPHAUL C, LI JZ, et al.A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis[J].J Biol Chem, 2010, 285 (9) :6706-6715.

[37]ROMEO S, KOZLITINA J, XING C, et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2008, 40 (2) :1461-1465.

[38]SOOKOIAN S, PIROLA CJ.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease[J].Hepatology, 2011, 53 (6) :1883-1894.

[39]LIU YL, REEVES HL, BURT AD, et al.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease[J].Nat Commun, 2014, 5 (4) :4309.

[40]KOZLITINA J, SMAGRIS E, STENDER S, et al.Exomewide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2014, 46 (4) :352-356.

[41]SENATES E, YILMAZ Y, COLAK Y, et al.Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease[J].Metab Syndr Relat Disord, 2011, 9 (4) :287-290.

[42]JIA L, WANG TC, LI Q.Iron overload and study on the relationship between the pathogenesis of nonalcoholic fatty liver disease[J].Chin J PHM, 2015, 31 (2) :193-194. (in Chinese) 贾丽, 王天初, 李权.铁超载与非酒精性脂肪肝发病关系研究近况[J].中国公共卫生管理, 2015, 31 (2) :193-194.

[43]FENG HP, REN YL.Signiifcance of serum ferritin in patients with non-alcoholic fatty liver disease[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :113-115. (in Chinese) 冯红萍, 任艳玲.非酒精性脂肪性肝病患者血清铁蛋白检测的意义[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :113-115.

[44]CAO W, ZHAO CY.Mitochondrial dysfunction and nonalcoholic fatty liver disease[J].Chin Hepatol, 2011, 16 (3) :256-259. (in Chinese) 曹伟, 赵彩彦.线粒体功能不全与非酒精性脂肪性肝病[J].肝脏, 2011, 16 (3) :256-259.

[45]GUPTA D, RADHAKRISHNAN M, KURHE Y.Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice[J].Steroids, 2015, 96 (11) :95-102.

施引文献

资源附件(0)

访问统计